| Members |
targetComponentId |
| Human leukocyte antigen A 3101 present |
Human leukocyte antigen A*31:01 detected (finding) |
| Human leukocyte antigen B 1502 present |
HLA-B*15:02 detected |
| Human leukocyte antigen B 5701 present |
HLA-B*57:01 detected |
| Human menopausal gonadotrophins 150iu injection |
Human menopausal gonadotropin only product |
| Human menopausal gonadotrophins 150iu injection |
Human menopausal gonadotropin only product |
| Human menopausal gonadotrophins 150units(FSH) injection (pdr for recon)+solvent |
Human menopausal gonadotropin only product |
| Human menopausal gonadotrophins 75iu injection |
Pituitary follicle stimulating hormone 75 unit and pituitary luteinizing hormone 75 unit powder for solution for injection vial |
| Human menopausal gonadotrophins 75iu injection |
Pituitary follicle stimulating hormone 75 unit and pituitary luteinizing hormone 75 unit powder for solution for injection vial |
| Human menopausal gonadotrophins 75units(FSH) powder and solvent for injection solution vial |
Pituitary follicle stimulating hormone 75 unit and pituitary luteinizing hormone 75 unit powder for solution for injection vial |
| Human normal immunoglobulin 10g i-v infusion (pdr for recon) |
Product containing only normal human immunoglobulin in parenteral dose form (medicinal product form) |
| Human normal immunoglobulin 10g i-v infusion (pdr for recon)+diluent |
Product containing only normal human immunoglobulin in parenteral dose form (medicinal product form) |
| Human normal immunoglobulin 10g infusion solution vial |
Product containing precisely human immunoglobulin G 10 gram/1 vial powder for conventional release solution for injection (clinical drug) |
| Human normal immunoglobulin 12g infusion solution vial |
Product containing only normal human immunoglobulin in parenteral dose form (medicinal product form) |
| Human normal immunoglobulin 16% injection solution vial |
Product containing precisely human immunoglobulin G 160 milligram/1 milliliter conventional release solution for injection (clinical drug) |
| Human normal immunoglobulin 1g infusion solution vial |
Product containing only normal human immunoglobulin in parenteral dose form (medicinal product form) |
| Human normal immunoglobulin 2.5g i-v infusion (pdr for recon) |
Product containing only normal human immunoglobulin in parenteral dose form (medicinal product form) |
| Human normal immunoglobulin 2.5g i-v infusion (pdr for recon)+diluent |
Product containing only normal human immunoglobulin in parenteral dose form (medicinal product form) |
| Human normal immunoglobulin 2.5g infusion solution vial |
Product containing precisely human immunoglobulin G 2.5 gram/1 vial powder for conventional release solution for injection (clinical drug) |
| Human normal immunoglobulin 250mg injection solution vial |
Product containing only normal human immunoglobulin in parenteral dose form (medicinal product form) |
| Human normal immunoglobulin 3g infusion solution vial |
Product containing precisely human immunoglobulin G 3 gram/1 vial powder for conventional release solution for injection (clinical drug) |
| Human normal immunoglobulin 500mg i-v infusion (pdr for recon) |
Product containing only normal human immunoglobulin in parenteral dose form (medicinal product form) |
| Human normal immunoglobulin 500mg i-v infusion (pdr for recon)+diluent |
Product containing only normal human immunoglobulin in parenteral dose form (medicinal product form) |
| Human normal immunoglobulin 500mg infusion solution vial |
Product containing only normal human immunoglobulin in parenteral dose form (medicinal product form) |
| Human normal immunoglobulin 5g i-v infusion (pdr for recon) |
Product containing only normal human immunoglobulin in parenteral dose form (medicinal product form) |
| Human normal immunoglobulin 5g i-v infusion (pdr for recon)+diluent |
Product containing only normal human immunoglobulin in parenteral dose form (medicinal product form) |
| Human normal immunoglobulin 5g infusion solution vial |
Product containing precisely human immunoglobulin G 5 gram/1 vial powder for conventional release solution for injection (clinical drug) |
| Human normal immunoglobulin 6g conventional release solution for injection vial |
Human immunoglobulin G 6 G powder for solution for injection vial |
| Human normal immunoglobulin 6g infusion solution vial |
Human immunoglobulin G 6 G powder for solution for injection vial |
| Human normal immunoglobulin 750mg injection solution vial |
Product containing only normal human immunoglobulin in parenteral dose form (medicinal product form) |
| Human papilloma virus type 9 vaccine |
Vaccine product containing only Human papillomavirus 6, 11, 16, 18, 31, 33, 45, 52 and 58 antigens (medicinal product) |
| Human papillomavirus group |
Human papillomavirus |
| consentement au test du papillomavirus humain refusé |
Screening for Human papillomavirus declined (situation) |
| Human protein C 1000iu injection (pdr for recon)+solvent |
Product containing precisely human protein C 1000 unit/1 vial powder for conventional release solution for injection (clinical drug) |
| Human protein C 1000iu injection powder for reconstitution+solvent |
Product containing precisely human protein C 1000 unit/1 vial powder for conventional release solution for injection (clinical drug) |
| Human protein C 500iu injection (pdr for recon)+solvent |
Product containing precisely human protein C 500 unit/1 vial powder for conventional release solution for injection (clinical drug) |
| Human protein C 500iu injection powder for reconstitution+solvent |
Product containing precisely human protein C 500 unit/1 vial powder for conventional release solution for injection (clinical drug) |
| anaphylaxie causée par une protéine humaine |
Anaphylaxis |
| Human recombinant choriogonadotropin alfa 250micrograms injection powder for reconstitution + solvent |
Choriogonadotropin alfa only product in parenteral dose form |
| Human tick-borne encephalitis immunoglobulin injection solution 1 mL vial |
Human tick borne encephalitis immunoglobulin only product in parenteral dose form |
| Human tick-borne encephalitis immunoglobulin injection solution 10 mL vial |
Human tick borne encephalitis immunoglobulin only product in parenteral dose form |
| Human tick-borne encephalitis immunoglobulin injection solution 2 mL vial |
Human tick borne encephalitis immunoglobulin only product in parenteral dose form |
| Human tick-borne encephalitis immunoglobulin injection solution 5 mL vial |
Human tick borne encephalitis immunoglobulin only product in parenteral dose form |
| Human vaccination |
Active immunization |
| Human vaccinia immune globulin 50mg/mL injection solution 50mL vial |
Vaccinia human immune globulin 50 mg/mL solution for injection |
| environnement humide |
Humid environment (finding) |
| Humulin insulin adverse reaction |
Adverse reaction caused by human insulin (disorder) |
| Husband of subject |
Husband |
| Hyaline membrane disease |
Respiratory distress syndrome in the newborn |
| Hyaluronidase 1500unt/10mL injection |
Product containing precisely bovine hyaluronidase 150 unit/1 milliliter conventional release solution for injection (clinical drug) |
| Hyaluronidase 150unt/mL injection solution 10mL vial |
Product containing precisely bovine hyaluronidase 150 unit/1 milliliter conventional release solution for injection (clinical drug) |
| Hyaluronidase 150unt/mL injection solution 1mL vial |
Product containing precisely bovine hyaluronidase 150 unit/1 milliliter conventional release solution for injection (clinical drug) |
| Hydatidiform mole, no International Classification of Diseases for Oncology subtype |
Hydatidiform mole, benign (morphologic abnormality) |
| hydralazine hydrochloride 20 mg, fiole de poudre pour injection |
Hydralazine hydrochloride 20 mg powder for solution for injection vial |
| Hydrazide antituberculosis agent |
Antituberculosis agent |
| Hydrazide antituberculosis drug adverse reaction |
Isoniazid adverse reaction |
| Hydrocephalic disproportion NOS |
Hydrocephalic disproportion |
| Hydrocephalic disproportion unspecified |
Hydrocephalic disproportion |
| Hydrochlorothiazide + quinapril hydrochloride |
Product containing hydrochlorothiazide and quinapril (medicinal product) |
| Hydrochlorothiazide + quinapril hydrochloride 12.5mg/10mg tablet |
Hydrochlorothiazide 12.5 mg and quinapril (as quinapril hydrochloride) 10 mg oral tablet |
| Hydrochlorothiazide 25mg |
Hydrochlorothiazide 25 mg oral tablet |
| Hydrocortisone 1% + Pramocaine 1% conventional release rectal foam |
Hydrocortisone and pramocaine only product |
| Hydrocortisone 1% + Pramocaine 1% foam enema |
Hydrocortisone and pramocaine only product |
| Hydrocortisone 100mg powder and solvent for injection solution vial |
Hydrocortisone (as hydrocortisone sodium succinate) 100 mg powder for solution for injection vial |
| Hydrocortisone 100mg/60mL |
Product containing precisely hydrocortisone 1.67 milligram/1 milliliter conventional release rectal suspension (clinical drug) |
| Hydrocortisone 100mg/60mL enema |
Product containing precisely hydrocortisone 1.67 milligram/1 milliliter conventional release rectal suspension (clinical drug) |
| Hydrocortisone 2% topical lotion |
Hydrocortisone acetate 20 mg/mL cutaneous lotion |
| Hydrocortisone acetate 1% eye drops |
Hydrocortisone 10 mg/mL eye solution |
| Hydrocortisone acetate 2.5% cream |
Product containing precisely hydrocortisone 25 milligram/1 milliliter conventional release cutaneous cream (clinical drug) |
| Hydrocortisone acetate+neomycin sulfate 1.5%/0.5% eye drops |
Hydrocortisone acetate 15 mg/mL and neomycin (as neomycin sulfate) 5 mg/mL eye solution |
| Hydrocortisone cypionate 10mg/5mL suspension |
Product containing precisely hydrocortisone 2 milligram/1 milliliter conventional release oral suspension (clinical drug) |
| Hydrocortisone/neomycin cream |
Hydrocortisone acetate 10 mg/g and neomycin sulfate 5 mg/g cutaneous cream |
| Hydrolyase |
Hydrolyase |
| Hydromorphone hydrochloride 100% powder |
Hydromorphone only product |
| Hydromorphone hydrochloride 12mg m/r capsule |
Product containing only hydromorphone in oral dose form (medicinal product form) |
| Hydromorphone hydrochloride 12mg prolonged-release oral capsule |
Product containing only hydromorphone in oral dose form (medicinal product form) |
| Hydromorphone hydrochloride 1mg/mL injection solution ampule |
Hydromorphone hydrochloride 1 mg/mL solution for injection |
| Hydromorphone hydrochloride 32mg m/r capsule |
Product containing only hydromorphone in oral dose form (medicinal product form) |
| Hydromorphone hydrochloride 32mg prolonged-release oral capsule |
Product containing only hydromorphone in oral dose form (medicinal product form) |
| Hydromorphone hydrochloride 4mg/mL injection solution ampule |
Hydromorphone hydrochloride 4 mg/mL solution for injection |
| Hydrous wool fat+zinc oxide 4/8% conventional release cutaneous cream |
Lanolin and zinc oxide only product in cutaneous dose form |
| Hydrous wool fat+zinc oxide 4/8% cream |
Lanolin and zinc oxide only product in cutaneous dose form |
| Hydroxocobalamin 1mg/mL injection 1mL ampule |
Product containing precisely hydroxocobalamin (as hydroxocobalamin acetate) 1 milligram/1 milliliter conventional release solution for injection (clinical drug) |
| Hydroxocobalamin 2.5g powder for conventional release solution for injection vial |
Product containing only hydroxocobalamin in parenteral dose form (medicinal product form) |
| Hydroxocobalamin 2.5g powder for injection solution vial + diluent |
Product containing only hydroxocobalamin in parenteral dose form (medicinal product form) |
| Hydroxyethylcellulose 0.44% conventional release eye drops |
Product containing only hyetellose (medicinal product) |
| Hydroxyethylcellulose 0.44% single-use eye drops |
Product containing only hyetellose (medicinal product) |
| Hydroxypropyl methylcellulose 0.32% conventional release eye drops |
Hypromellose 3.2 mg/mL eye solution |
| Hydroxypropyl methylcellulose 0.32% single-use eye drops |
Hypromellose 3.2 mg/mL eye solution |
| Hydroxypropylmethylcellulose 2% eye drops |
Product containing precisely hypromellose 2 milligram/1 milliliter conventional release eye solution (clinical drug) |
| Hyoscine butylbromide allergy |
Allergy to hyoscine |
| Hyoscine hydrobromide 0.125% eye drops |
Hyoscine (as hyoscine hydrobromide) 1.25 mg/mL eye solution |
| Hyoscine hydrobromide 0.25% eye drops |
Product containing precisely scopolamine (as scopolamine hydrobromide) 2.5 milligram/1 milliliter conventional release eye solution (clinical drug) |
| Hyoscine hydrobromide 0.5% eye drops |
Hyoscine (as hyoscine hydrobromide) 5 mg/mL eye solution |
| Hyoscine hydrobromide allergy |
Allergy to hyoscine |
| Hyoscyamine sulfate 0.031mg/1 mL |
Hyoscyamine only product |
| Hyoscyamine sulfate 0.125mg/5mL elixir |
Hyoscyamine sulfate 25 microgram/mL oral solution |
| Hyoscyamine sulfate 0.125mg/5mL liquid |
Hyoscyamine sulfate 25 microgram/mL oral solution |
| Hyoscyamine sulfate 0.125mg/mL liquid |
Hyoscyamine sulfate 25 microgram/mL oral solution |
| Hyperalphaglobulinemia |
Hyperalphaglobulinaemia |
| Hyperbetaglobulinemia |
Hyperbetaglobulinemia |
| Hypercalcemia caused by thiazide AND vitamin A |
Hypercalcemia caused by thiazide and/or retinol (disorder) |
FHIR